ClinicalTrials.gg
CompletedNCT01525589Updated Sep 25, 2020Results posted

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

A Phase 2 interventional study of PM01183 in Breast Cancer, sponsored by PharmaMar. Completed at 9 sites in 2 countries. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-25.

Sponsored by PharmaMar · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in Metastatic Breast Cancer (MBC) patients, to evaluate the safety profile of this PM01183 to analyze the pharmacokinetics (PK) and PK/PD (pharmacokinetic/pharmacodynamic) correlations and to evaluate the pharmacogenomic (PGx) expression profile in tumor samples.

Read the detailed description

A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer to assess the antitumor activity of PM01183 in terms of overall response rate (ORR), duration of response (DR),clinical benefit [ORR or stable disease lasting over three months (SD > 3 months)], progression free survival (PFS), and one-year overall survival (1y-OS) and to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in MBC patients, to explore the activity of PM01183 in specific breast cancer subpopulations according to hormonal receptor status, HER-2 overexpression, number and/or type of prior therapies, or according to other available histological/molecular classifications, to evaluate the safety profile of this PM01183 administration schedule [Day 1 every three weeks (q3wk)] in this patient population, to analyze the pharmacokinetics (PK) of PM01183 in this patient population, to explore PK/PD (pharmacokinetic/ pharmacodynamic) correlations, if applicable and to evaluate the pharmacogenomic (PGx) expression profile of selected putative markers potentially predictive of response to PM01183, in tissues from tumor samples.

02

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast cancer
  • PM01183
  • lurbinectedin
  • Pharma Mar
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 111 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women ≥ 18 and ≤ 75 years of age.
  • Voluntary signed form (ICF).
  • Proven diagnosis of breast cancer (MBC).
  • At least one, but no more than three, prior chemotherapy regimens for MBC.
  • Patients with known overexpressing MBC must have failed at least one prior trastuzumab-containing regimen for metastatic disease.
  • Disease evaluable for response by specific appropriate criteria.
  • No or minimal disease-related symptoms not affecting patient daily activities.
  • Adequate major organ function (normal or minimal alteration in liver, kidney, hematological, metabolic and cardiac function)
  • Wash out periods prior to Day 1 of Cycle 1:

At least three weeks since the last chemotherapy (six weeks in some particular cases) and At least four weeks since the last radiotherapy (RT) > 30 Gy) and At least one week since the last hormonal therapy and At least two weeks since the last biological/ therapy

  • Minimal or no ongoing toxicity from immediately prior therapy according to specific appropriate criteria. Mild ongoing toxicity is allowed in case of alopecia, skin toxicity, fatigue and/or finger numbness or tumbling.
  • Patients of must agree to use a medically approved method until at least six weeks after the last study drug administration.
  • Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1)
  • Prior treatment with PARP inhibitors (Patients in Cohort A1)

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with PM01183 or trabectedin.
  • Extensive prior RT.
  • Prior or concurrent malignant disease unless cured for more than five years.
  • Exceptions are breast cancer in the other breast.
  • Uncommon or rare subtypes of breast cancer.
  • Symptomatic or progressive .
  • Bone-limited and exclusively .
  • Relevant diseases or clinical situations which may increase patient's risk:

History of cardiac disease. Moderate breathing difficulties or oxygen requirement Active uncontrolled infection. Unhealed wound or presence of any external drainage. Chronically active viral hepatitis. patients, including those known to be infected by (HIV).

Known muscular disease or functional alteration

  • Pregnant or breastfeeding women.
  • Impending need for immediate RT for symptomatic relief.
  • Limitation of the patient's ability to comply with the treatment or to follow-up the protocol.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    PM01183

    Drug: PM01183

Interventions

  • PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    The overall response rate is defined as the percentage of patients with a confirmed response, either complete response (CR) or partial response (PR), according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR \>=30% decrease in the sum of the longest diameter of target lesions.

    Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment

  2. Overall Response

    Overall Response Rate (ORR) in the population evaluable for efficacy according to RECIST v.1.1. ORR was defined as the percentage of patients with a confirmed response, either CR or PR, according to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions; SD, stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; TF, treatment failure.

    Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment

Secondary outcomes

  1. Duration of Response

    Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions.

    Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment

  2. Duration of Response Rate at 6 Months

    Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions.

    Time frame: Time between the response criteria date and the date when disease progression, recurrence or death was documented, up to 6 months

  3. Duration of Response Rate at 12 Months

    Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions.

    Time frame: Time between the response criteria date and the date when disease progression, recurrence or death was documented, up to 12 months

  4. Clinical Benefit Rate

    Clinical benefit, defined as the percentage of patients with ORR or SD lasting over three months (SD \>3 months). The overall response rate is defined as the percentage of patients with a confirmed response, either complete response (CR) or partial response (PR), according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR \>=30% decrease in the sum of the longest diameter of target lesions. SD, stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment

  5. Progression-free Survival (PFS)

    Progression-free survival (PFS) is defined as the period of time from the date of first infusion to the date of progression disease, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: 36 months

  6. Progression-free Survival at 3 Months

    Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 3 months

  7. Progression-free Survival at 6 Months

    Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 6 months

  8. Progression-free Survival at 12 Months

    Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 12 months

  9. Overall Survival (OS)

    Overall survival (OS) will be defined as time from the date of first infusion to the date of death or last contact

    Time frame: 36 months

  10. Overall Survival Rate at 12 Months

    Overall survival (OS), defined as the time from the date of first infusion to the date of death or last contact

    Time frame: Time from the date of first infusion to the date of death or last contact, up to 12 months

  11. Overall Survival Rate at 18 Months

    Overall survival (OS), defined as the time from the date of first infusion to the date of death or last contact.

    Time frame: Time from the date of first infusion to the date of death or last contact, up to 18 months

07

Results

Posted Sep 25, 2020

Participant flow

The first patient was included on 27JUN12 and the first study treatment administration was on 28JUN12. The cutoff date for the results was 24OCT18. A total of 111 patients were included in the 3 cohorts of the study: 56 in Cohort A (BRCA+), 20 in Cohort A1 (BRCA+/PARPi), 35 in Cohort B (Unselected).

Participant flow — Overall Study
MilestoneCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Started562035
Completed000
Not completed562035
Withdrew: Non-treatment-related ae100
Withdrew: Progressive disease481529
Withdrew: Never treated200
Withdrew: Physician decision422
Withdrew: Death002
Withdrew: Treatment-related ae112
Withdrew: Other reasons010
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryOverall Response Rate (ORR)

The overall response rate is defined as the percentage of patients with a confirmed response, either complete response (CR) or partial response (PR), according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR \>=30% decrease in the sum of the longest diameter of target lesions.

Time frame:
Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Reported as:
Number · percentage
Overall Response Rate (ORR)
percentageCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Overall Response Rate (ORR)40.7 (27.6 to 55.0)5.0 (0.1 to 24.9)8.8 (1.9 to 23.7)
PrimaryOverall Response

Overall Response Rate (ORR) in the population evaluable for efficacy according to RECIST v.1.1. ORR was defined as the percentage of patients with a confirmed response, either CR or PR, according to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions; SD, stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; TF, treatment failure.

Time frame:
Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Reported as:
Count of participants · Participants
Overall Response
ParticipantsCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
CR200
PR2013
SD24917
PD81013
TF001
SecondaryDuration of Response

Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions.

Time frame:
Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Reported as:
Median · months
Duration of Response
monthsCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Duration of Response6.3 (3.4 to 12.7)2.7 (NA to NA)3.6 (2.1 to 16.1)
Statistical analysis
  • Cohort A (BRCA+) vs Cohort A1 (BRCA+/PARPi) vs Cohort B (Unselected) · Log Rank · p = 0.0909
SecondaryDuration of Response Rate at 6 Months

Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions.

Time frame:
Time between the response criteria date and the date when disease progression, recurrence or death was documented, up to 6 months
Reported as:
Number · percentage of participants
Duration of Response Rate at 6 Months
percentage of participantsCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Duration of Response Rate at 6 Months53.1 (31.8 to 74.4)0 (NA to NA)33.3 (0 to 86.7)
SecondaryDuration of Response Rate at 12 Months

Duration of response (DoR), defined as the time between the date when the response criteria (PR or CR, whichever was first reached) were fulfilled to the first date when disease progression (PD), recurrence or death was documented. According to the RECIST v.1.1 for target lesions and assessed by MRI: CR, complete response: Disappearance of all target lesions; PD, progressive disease: 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR, partial response: \>=30% decrease in the sum of the longest diameter of target lesions.

Time frame:
Time between the response criteria date and the date when disease progression, recurrence or death was documented, up to 12 months
Reported as:
Number · percentage of participants
Duration of Response Rate at 12 Months
percentage of participantsCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Duration of Response Rate at 12 Months33.8 (13.5 to 54.1)0 (NA to NA)33.3 (0 to 86.7)
SecondaryClinical Benefit Rate

Clinical benefit, defined as the percentage of patients with ORR or SD lasting over three months (SD \>3 months). The overall response rate is defined as the percentage of patients with a confirmed response, either complete response (CR) or partial response (PR), according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions and assessed by MRI: CR, Disappearance of all target lesions; PR \>=30% decrease in the sum of the longest diameter of target lesions. SD, stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Minimum 10-12 months if negative results and up to 26-28 months if study is to be complete the targeted enrollment
Reported as:
Number · percentage of participants
Clinical Benefit Rate
percentage of participantsCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Clinical Benefit Rate61.1 (46.9 to 74.1)40.0 (19.1 to 63.9)32.4 (17.4 to 50.5)
SecondaryProgression-free Survival (PFS)

Progression-free survival (PFS) is defined as the period of time from the date of first infusion to the date of progression disease, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
36 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Progression-free Survival (PFS)4.6 (3.0 to 6.2)1.4 (1.3 to 3.9)2.5 (1.3 to 3.4)
Statistical analysis
  • Cohort A (BRCA+) vs Cohort A1 (BRCA+/PARPi) vs Cohort B (Unselected) · Log Rank · p = 0.002
SecondaryProgression-free Survival at 3 Months

Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 3 months
Reported as:
Number · percentage of participants
Progression-free Survival at 3 Months
percentage of participantsCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Progression-free Survival at 3 Months63.5 (50.4 to 76.6)42.5 (20.3 to 64.7)35.5 (18.9 to 52.1)
SecondaryProgression-free Survival at 6 Months

Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 6 months
Reported as:
Number · percentage of participants
Progression-free Survival at 6 Months
percentage of participantsCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Progression-free Survival at 6 Months37.6 (24.2 to 50.9)21.3 (2.8 to 39.7)11.1 (0 to 22.6)
SecondaryProgression-free Survival at 12 Months

Progression-free survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Time from the date of first infusion to the date of PD, death (due to any cause), or last tumor evaluation, up to 12 months
Reported as:
Number · percentage of participants
Progression-free Survival at 12 Months
percentage of participantsCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Progression-free Survival at 12 Months20.5 (9.1 to 31.9)0 (0 to 0)3.7 (0 to 10.7)
SecondaryOverall Survival (OS)

Overall survival (OS) will be defined as time from the date of first infusion to the date of death or last contact

Time frame:
36 months
Reported as:
Median · months
Overall Survival (OS)
monthsCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Overall Survival (OS)18.6 (10.9 to 22.8)8.1 (4.6 to 14.6)12.1 (6.6 to 17.9)
Statistical analysis
  • Cohort A (BRCA+) vs Cohort A1 (BRCA+/PARPi) vs Cohort B (Unselected) · Log Rank · p = 0.0561
SecondaryOverall Survival Rate at 12 Months

Overall survival (OS), defined as the time from the date of first infusion to the date of death or last contact

Time frame:
Time from the date of first infusion to the date of death or last contact, up to 12 months
Reported as:
Number · percentage of participants
Overall Survival Rate at 12 Months
percentage of participantsCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Overall Survival Rate at 12 Months62.5 (49.0 to 75.9)29.7 (7.9 to 51.5)55.4 (37.9 to 73.0)
SecondaryOverall Survival Rate at 18 Months

Overall survival (OS), defined as the time from the date of first infusion to the date of death or last contact.

Time frame:
Time from the date of first infusion to the date of death or last contact, up to 18 months
Reported as:
Number · percentage of participants
Overall Survival Rate at 18 Months
percentage of participantsCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Overall Survival Rate at 18 Months53.4 (39.2 to 67.5)22.3 (1.6 to 42.9)27.7 (11.5 to 43.9)

Adverse events

Collected over Participants were assessed through study completion, aproximately 6 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A (BRCA+)40/54 (74.1%)14/54 (25.9%)54/54 (100%)
Cohort A1 (BRCA+/PARPi)13/20 (65%)5/20 (25%)20/20 (100%)
Cohort B (Unselected)30/35 (85.7%)8/35 (22.9%)34/35 (97.1%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
Febrile neutropeniaBlood and lymphatic system disorders7/542/200/35
ThrombocytopeniaBlood and lymphatic system disorders6/540/200/35
VomitingGastrointestinal disorders3/540/200/35
Staphylococcal bacteraemiaInfections and infestations0/541/200/35
FallInjury, poisoning and procedural complications0/541/200/35
Platelet count decreasedInvestigations1/541/200/35
DyspnoeaRespiratory, thoracic and mediastinal disorders2/541/200/35
Pleural effusionRespiratory, thoracic and mediastinal disorders0/541/200/35
Respiratory failureRespiratory, thoracic and mediastinal disorders0/541/200/35
SyncopeNervous system disorders0/541/200/35
Most frequent other events
Showing 10 of 95
Most frequent other events
EventCohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)
fatigueGeneral disorders48/5410/2030/35
nauseaGastrointestinal disorders43/5415/2020/35
neutropeniaBlood and lymphatic system disorders24/5411/207/35
NeutropeniaInvestigations24/5411/207/35
constipationGastrointestinal disorders23/549/209/35
vomitingGastrointestinal disorders23/547/2010/35
Decreased appetiteMetabolism and nutrition disorders15/546/205/35
HeadacheNervous system disorders16/546/205/35
diarrhoeaGastrointestinal disorders16/544/205/35
CoughRespiratory, thoracic and mediastinal disorders16/542/206/35

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)Total
<=18 years0000
Between 18 and 65 years511930100
>=65 years51511
Age, Continuous
Age, Continuous(years)Cohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)Total
Median42.5 (30 to 73)45.0 (31 to 66)52.0 (32 to 70)45.0 (30 to 73)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)Total
Female562035111
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)Total
Race — Caucasian50163298
Race — Black2013
Race — Asian1102
Race — Hispanic2125
Race — Unknown1203
Region of Enrollment
Region of Enrollment(participants)Cohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)Total
United States3516960
Spain2142651
ECOG PS
ECOG PS(Participants)Cohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)Total
PS 032102264
PS 124101347
Sites of disease at diagnosis
Sites of disease at diagnosis(Participants)Cohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)Total
Left breast26111855
Right breast2891552
Bilateral2024
Histology type at diagnosis
Histology type at diagnosis(Participants)Cohort A (BRCA+)Cohort A1 (BRCA+/PARPi)Cohort B (Unselected)Total
Ductal carcinoma542034108
Lobular carcinoma2002
Lobular and ductal carcinoma0011

15 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • Stanford Women's Cancer Center
    Stanford, California 94305, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Weill Cornell Medical College - New York Presbyterian Hospital
    New York, New York 10065, United States
  • Abramson Cancer Center - Hospital of the University of Pennsylvania at Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Complexo Hospitalario Universitario A Coruña
    A Coruna, A Coruña 15006, Spain
  • Complexo Hospitalario Universitario de Santiago
    Santiago de Compostela, A Coruña 15706, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
09

References and documents

Publications

  • Fernandez-Teruel C, Lubomirov R, Fudio S. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin. J Clin Pharmacol. 2021 Sep;61(9):1206-1219. doi: 10.1002/jcph.1886. Epub 2021 Jun 9. PubMed 33914350 ↗
  • Cruz C, Llop-Guevara A, Garber JE, Arun BK, Perez Fidalgo JA, Lluch A, Telli ML, Fernandez C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Perez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmana J, Isakoff SJ. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21. Erratum In: J Clin Oncol. 2018 Nov 20;36(33):3348. doi: 10.1200/JCO.18.01630. J Clin Oncol. 2019 Feb 1;37(4):362. doi: 10.1200/JCO.18.02205. PubMed 30240327 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Oct 2018, 76 months.

Results were first posted in Sep 2020, 1 year 11 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 76 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2012
First posted
Feb 3, 2012
StartActual
Jun 13, 2012
Primary completionActual
Oct 2018
CompletionActual
Oct 2018
Results first posted
Sep 25, 2020
Last update
Sep 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01525589
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
Feb 3, 2012
Start date
Jun 13, 2012
Primary completion
Oct 2018
Completion
Oct 2018
Results posted
Sep 25, 2020
Last update
Sep 25, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PM 01183

Start the discussion